|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Kymera Therapeutics, Inc. (KYMR) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
84,917,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kymera Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. Co.'s proprietary targeted protein degradation platform, which Co. refers to as Pegasus™, allows Co. to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. Co. has utilized its Pegasus™ platform to design protein degraders focused in the areas of immunology-inflammation and oncology, and Co. continues to apply its platform's capabilities to additional therapeutic areas.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
972,667 |
972,667 |
1,386,773 |
| Total Buy Value |
$0 |
$42,797,348 |
$42,797,348 |
$48,098,719 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
5 |
| Total Shares Sold |
176,910 |
237,334 |
259,362 |
1,715,804 |
| Total Sell Value |
$9,573,423 |
$12,453,346 |
$13,205,848 |
$72,062,725 |
| Total People Sold |
4 |
7 |
8 |
11 |
| Total Sell Transactions |
5 |
11 |
17 |
45 |
| End Date |
2025-07-20 |
2025-04-18 |
2024-10-18 |
2023-10-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gollob Jared |
Chief Medical Officer |
• – – |
2025-10-15 |
4 |
AS |
$60.37 |
$3,659,254 |
D/D |
(59,576) |
109,992 |
|
- |
|
| Gollob Jared |
Chief Medical Officer |
• – – |
2025-10-15 |
4 |
OE |
$1.31 |
$84,185 |
D/D |
51,209 |
169,568 |
|
- |
|
| Albers Jeffrey W. |
|
– • – |
2025-10-13 |
4 |
AS |
$59.19 |
$295,949 |
D/D |
(5,000) |
0 |
|
- |
|
| Albers Jeffrey W. |
|
– • – |
2025-10-13 |
4 |
OE |
$10.34 |
$51,700 |
D/D |
5,000 |
5,000 |
|
- |
|
| Gollob Jared |
Chief Medical Officer |
• – – |
2025-10-13 |
4 |
AS |
$60.00 |
$186,840 |
D/D |
(3,114) |
118,359 |
|
- |
|
| Gollob Jared |
Chief Medical Officer |
• – – |
2025-10-13 |
4 |
OE |
$1.31 |
$2,448 |
D/D |
1,473 |
121,473 |
|
- |
|
| Jacobs Bruce N. |
Chief Financial Officer |
• – – |
2025-09-17 |
4 |
AS |
$50.00 |
$3,961,380 |
D/D |
(79,220) |
227,409 |
|
- |
|
| Jacobs Bruce N. |
Chief Financial Officer |
• – – |
2025-09-17 |
4 |
OE |
$2.08 |
$164,778 |
D/D |
79,220 |
306,629 |
|
- |
|
| Mainolfi Nello |
Chief Executive Officer |
• • – |
2025-09-16 |
4 |
AS |
$49.00 |
$1,470,000 |
D/D |
(30,000) |
660,482 |
|
- |
|
| Mainolfi Nello |
Chief Executive Officer |
• • – |
2025-09-16 |
4 |
OE |
$2.08 |
$62,400 |
D/D |
30,000 |
690,482 |
|
- |
|
| Adams Brian |
Chief Legal Officer |
• – – |
2025-09-03 |
4 |
A |
$0.00 |
$0 |
D/D |
52,500 |
52,500 |
|
- |
|
| Lampert Mark N |
See Remarks and Footnotes |
– • – |
2025-06-30 |
4 |
B |
$44.00 |
$13,955,348 |
D/D |
317,167 |
353,412 |
2.39 |
- |
|
| Baker Julian |
|
– • – |
2025-06-30 |
4 |
B |
$44.00 |
$28,842,000 |
I/I |
655,500 |
6,117,295 |
0.01 |
- |
|
| Ridloff Elena |
|
– • – |
2025-06-11 |
4 |
AS |
$50.00 |
$225,000 |
D/D |
(4,500) |
0 |
|
- |
|
| Ridloff Elena |
|
– • – |
2025-06-11 |
4 |
OE |
$20.29 |
$91,305 |
D/D |
4,500 |
4,500 |
|
- |
|
| Ridloff Elena |
|
– • – |
2025-06-03 |
4 |
AS |
$45.50 |
$553,200 |
D/D |
(12,000) |
0 |
|
- |
|
| Ridloff Elena |
|
– • – |
2025-06-03 |
4 |
OE |
$27.67 |
$332,040 |
D/D |
12,000 |
12,000 |
|
- |
|
| Mainolfi Nello |
Chief Executive Officer |
• • – |
2025-06-03 |
4 |
AS |
$49.00 |
$1,470,000 |
D/D |
(30,000) |
660,482 |
|
- |
|
| Mainolfi Nello |
Chief Executive Officer |
• • – |
2025-06-03 |
4 |
OE |
$2.08 |
$62,400 |
D/D |
30,000 |
690,482 |
|
- |
|
| Albers Jeffrey W. |
|
– • – |
2025-06-03 |
4 |
AS |
$49.00 |
$311,101 |
D/D |
(6,349) |
0 |
|
- |
|
| Albers Jeffrey W. |
|
– • – |
2025-06-03 |
4 |
OE |
$10.34 |
$65,649 |
D/D |
6,349 |
6,349 |
|
- |
|
| Esposito Pamela |
|
– • – |
2025-06-03 |
4 |
AS |
$49.04 |
$245,186 |
D/D |
(5,000) |
0 |
|
- |
|
| Esposito Pamela |
|
– • – |
2025-06-03 |
4 |
OE |
$29.55 |
$147,750 |
D/D |
5,000 |
5,000 |
|
- |
|
| Chadwick Jeremy G |
Chief Operating Officer |
• – – |
2025-05-23 |
4 |
S |
$29.30 |
$75,436 |
D/D |
(2,575) |
66,420 |
|
- |
|
| Goodman Noah |
Chief Business Officer |
• – – |
2025-04-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
81 |
|
- |
|
262 Records found
|
|
Page 1 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
